Investigation of 47Sc-Radiolabeled PDGFRβ-Targeted Affibody in SPECT Imaging and Radiotherapy of Pancreatic Cancer

Investigation of 47Sc-Radiolabeled PDGFRβ-Targeted Affibody in SPECT Imaging and Radiotherapy of Pancreatic Cancer | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Investigation of 47Sc-Radiolabeled PDGFRβ-Targeted Affibody in SPECT Imaging and Radiotherapy of Pancreatic Cancer Ruomeng Liu, Dongping Su, Yuhao Liao, Zhao Li, Bo Li, Yunming Chen, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7549251/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 05 Jan, 2026 Read the published version in BMC Cancer → Version 1 posted 12 You are reading this latest preprint version Abstract Pancreatic cancer is a malignant solid tumor that contains a large number of cancer-associated fibroblasts (CAFs). Therefore, it is crucial to evaluate the disease progression of the tumor and plan radionuclide therapy through the molecular imaging of CAF biomarkers. Platelet-derived growth factor receptor β (PDGFRβ) was found that it was highly expressed on fibroblasts, and a specific affinity probe Z PDGFRβ that binds to PDGFRβ was successfully developed. In this study, 47 Sc was used to label the affibody targeting PDGFRβ to explore its distribution characteristics in pancreatic cancer and the therapeutic effect of radionuclides. 47 Sc was produced via thermal neutron irradiated enriched 46 Ca with radionuclide purity over 99.9%. The Z PDGFRβ affibody was radiolabeled by 47 Sc to obtain a 47 Sc-DOTA-Z PDGFRβ conjugate with radiochemical purity higher than 99%. Biodistribution studies showed that tumor uptake of 47 Sc-DOTA-Z PDGFRβ reached 4.57 ± 2.12 at 1h post-injection, and 4.00 ± 0.71 at 96h postinjection. However, the uptake by the liver and the kidneys reached 10.44 ± 3.19, 49.90 ± 8.89 respectively at 1h postinjection, and then it drops to 2.20 ± 1.04 and 2.60 ± 0.27. Single-Photon Emission Computed Tomography (SPECT) imaging indicated specific uptake of 47 Sc-DOTA-Z PDGFRβ in PANC-2 pancreatic tumors. Therapeutic experiments revealed that 47 Sc has an effective anti-tumor ability similar to 177 Lu. Our research results indicated that the 47 Sc-DOTA-Z PDGFRβ conjugate exhibited remarkable targeting efficacy as a PDGFRβ-targeted radiotracer in SPECT imaging and also demonstrated favorable radiotherapy capabilities. SPECT imaging of 47 Sc ions also revealed the characteristic distribution patterns in cardiac, aortic, and hepatic regions, held significant implications for future pharmaceutical development and radiation side-effect prediction. Pancreatic cancer platelet derived growth factor receptor beta affibody 47Sc SPECT/CT radionuclide therapy Full Text Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 05 Jan, 2026 Read the published version in BMC Cancer → Version 1 posted Editorial decision: Revision requested 31 Oct, 2025 Reviews received at journal 29 Oct, 2025 Reviewers agreed at journal 28 Oct, 2025 Reviewers agreed at journal 18 Oct, 2025 Reviews received at journal 10 Oct, 2025 Reviewers agreed at journal 08 Oct, 2025 Reviewers agreed at journal 11 Sep, 2025 Reviewers invited by journal 10 Sep, 2025 Editor assigned by journal 10 Sep, 2025 Editor invited by journal 10 Sep, 2025 Submission checks completed at journal 09 Sep, 2025 First submitted to journal 09 Sep, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7549251","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":513753334,"identity":"14599e5c-9a07-49db-a86a-0c743885b1a2","order_by":0,"name":"Ruomeng Liu","email":"","orcid":"","institution":"West China Hospital of Sichuan University","correspondingAuthor":false,"prefix":"","firstName":"Ruomeng","middleName":"","lastName":"Liu","suffix":""},{"id":513753335,"identity":"64b8ece2-5673-43b1-9a93-17d4e542af61","order_by":1,"name":"Dongping Su","email":"","orcid":"","institution":"The First Sub-institute of Nuclear Power Institute of China","correspondingAuthor":false,"prefix":"","firstName":"Dongping","middleName":"","lastName":"Su","suffix":""},{"id":513753336,"identity":"90763d70-c95f-4c7b-a773-6df8ff282553","order_by":2,"name":"Yuhao Liao","email":"","orcid":"","institution":"The First Sub-institute of Nuclear Power Institute of China","correspondingAuthor":false,"prefix":"","firstName":"Yuhao","middleName":"","lastName":"Liao","suffix":""},{"id":513753337,"identity":"4cd4d0b9-19ef-4acd-900b-485bc759cfb2","order_by":3,"name":"Zhao Li","email":"","orcid":"","institution":"West China Hospital of Sichuan University","correspondingAuthor":false,"prefix":"","firstName":"Zhao","middleName":"","lastName":"Li","suffix":""},{"id":513753338,"identity":"8649bf6d-66fa-4a6c-85d3-dd5ce28ebb82","order_by":4,"name":"Bo Li","email":"","orcid":"","institution":"The First Sub-institute of Nuclear Power Institute of China","correspondingAuthor":false,"prefix":"","firstName":"Bo","middleName":"","lastName":"Li","suffix":""},{"id":513753339,"identity":"cae3d99f-5a01-42e3-98d9-2befd96b9083","order_by":5,"name":"Yunming Chen","email":"","orcid":"","institution":"The First Sub-institute of Nuclear Power Institute of China","correspondingAuthor":false,"prefix":"","firstName":"Yunming","middleName":"","lastName":"Chen","suffix":""},{"id":513753340,"identity":"40ffbe34-d5ec-4c15-bfb8-04cd8500bcdf","order_by":6,"name":"Qi Cao","email":"","orcid":"","institution":"The First Sub-institute of Nuclear Power Institute of China","correspondingAuthor":false,"prefix":"","firstName":"Qi","middleName":"","lastName":"Cao","suffix":""},{"id":513753341,"identity":"ebaa148e-fb2b-488f-9945-0d2943bce8d7","order_by":7,"name":"Jinsong Zhang","email":"","orcid":"","institution":"The First Sub-institute of Nuclear Power Institute of China","correspondingAuthor":false,"prefix":"","firstName":"Jinsong","middleName":"","lastName":"Zhang","suffix":""},{"id":513753342,"identity":"3278aadd-9aa8-4c9c-a375-a7263d9ca2fa","order_by":8,"name":"Huawei Cai","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA9klEQVRIiWNgGAWjYBACAzjJzHyAgbEBIipBpBa2BFK0gAGPAXFazCWSn0l8KGCQ52/n+Sb5c0edvMEB5oO3eRjs8nBpsZyRZiY5w4DBcMZh3m3SvGcOG244wJZszcOQXIzTYTcSzG4DnZTAANRym7HtQILBAR4zaR6GA4kNOLWkf7v9B6hF/jDPs5s/2+qAWvi/EdCSY3YbGAgJBod52G7wtjGDbGHDr+XMm/KfPQYShhsPs5n/5m07bDjzMJux5RyDZNxajqdvNvjxx0Ze7vzhx4ZAh8nzHW9+eONNhR1OLVCAHBHMYKPwqx8Fo2AUjIJRgB8AAJgDVDA/Ook9AAAAAElFTkSuQmCC","orcid":"","institution":"West China Hospital of Sichuan University","correspondingAuthor":true,"prefix":"","firstName":"Huawei","middleName":"","lastName":"Cai","suffix":""}],"badges":[],"createdAt":"2025-09-06 07:53:08","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7549251/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7549251/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s12885-025-15506-w","type":"published","date":"2026-01-05T15:58:45+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":100070357,"identity":"1dfa4833-f025-4fb6-81c5-67b1a14443a3","added_by":"auto","created_at":"2026-01-12 16:17:32","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":767594,"visible":true,"origin":"","legend":"","description":"","filename":"RevisedManuscript0909.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7549251/v1_covered_56625b7d-99e3-4639-9f18-5e84185daedd.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Investigation of 47Sc-Radiolabeled PDGFRβ-Targeted Affibody in SPECT Imaging and Radiotherapy of Pancreatic Cancer","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-cancer","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bcan","sideBox":"Learn more about [BMC Cancer](http://bmccancer.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bcan/default.aspx","title":"BMC Cancer","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Pancreatic cancer, platelet derived growth factor receptor beta, affibody, 47Sc, SPECT/CT, radionuclide therapy","lastPublishedDoi":"10.21203/rs.3.rs-7549251/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7549251/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003ePancreatic cancer is a malignant solid tumor that contains a large number of cancer-associated fibroblasts (CAFs). Therefore, it is crucial to evaluate the disease progression of the tumor and plan radionuclide therapy through the molecular imaging of CAF biomarkers. Platelet-derived growth factor receptor β (PDGFRβ) was found that it was highly expressed on fibroblasts, and a specific affinity probe Z\u003csub\u003ePDGFRβ\u003c/sub\u003e that binds to PDGFRβ was successfully developed. In this study, \u003csup\u003e47\u003c/sup\u003eSc was used to label the affibody targeting PDGFRβ to explore its distribution characteristics in pancreatic cancer and the therapeutic effect of radionuclides. \u003csup\u003e47\u003c/sup\u003eSc was produced via thermal neutron irradiated enriched \u003csup\u003e46\u003c/sup\u003eCa with radionuclide purity over 99.9%. The Z\u003csub\u003ePDGFRβ\u003c/sub\u003e affibody was radiolabeled by \u003csup\u003e47\u003c/sup\u003eSc to obtain a \u003csup\u003e47\u003c/sup\u003eSc-DOTA-Z\u003csub\u003ePDGFRβ\u003c/sub\u003e conjugate with radiochemical purity higher than 99%. Biodistribution studies showed that tumor uptake of \u003csup\u003e47\u003c/sup\u003eSc-DOTA-Z\u003csub\u003ePDGFRβ\u003c/sub\u003e reached 4.57\u0026thinsp;\u0026plusmn;\u0026thinsp;2.12 at 1h post-injection, and 4.00\u0026thinsp;\u0026plusmn;\u0026thinsp;0.71 at 96h postinjection. However, the uptake by the liver and the kidneys reached 10.44\u0026thinsp;\u0026plusmn;\u0026thinsp;3.19, 49.90\u0026thinsp;\u0026plusmn;\u0026thinsp;8.89 respectively at 1h postinjection, and then it drops to 2.20\u0026thinsp;\u0026plusmn;\u0026thinsp;1.04 and 2.60\u0026thinsp;\u0026plusmn;\u0026thinsp;0.27. Single-Photon Emission Computed Tomography (SPECT) imaging indicated specific uptake of \u003csup\u003e47\u003c/sup\u003eSc-DOTA-Z\u003csub\u003ePDGFRβ\u003c/sub\u003e in PANC-2 pancreatic tumors. Therapeutic experiments revealed that \u003csup\u003e47\u003c/sup\u003eSc has an effective anti-tumor ability similar to \u003csup\u003e177\u003c/sup\u003eLu. Our research results indicated that the \u003csup\u003e47\u003c/sup\u003eSc-DOTA-Z\u003csub\u003ePDGFRβ\u003c/sub\u003e conjugate exhibited remarkable targeting efficacy as a PDGFRβ-targeted radiotracer in SPECT imaging and also demonstrated favorable radiotherapy capabilities. SPECT imaging of \u003csup\u003e47\u003c/sup\u003eSc ions also revealed the characteristic distribution patterns in cardiac, aortic, and hepatic regions, held significant implications for future pharmaceutical development and radiation side-effect prediction.\u003c/p\u003e","manuscriptTitle":"Investigation of 47Sc-Radiolabeled PDGFRβ-Targeted Affibody in SPECT Imaging and Radiotherapy of Pancreatic Cancer","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-09-17 19:41:31","doi":"10.21203/rs.3.rs-7549251/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-10-31T17:38:53+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-10-29T19:41:51+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"194170678768009288313199032891617603620","date":"2025-10-28T16:56:46+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"36388316954797796939344302361058122483","date":"2025-10-18T07:18:06+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-10-10T09:52:28+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"235486879264807804986461506597205513479","date":"2025-10-08T14:04:17+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"275217033576232227730285119848356662256","date":"2025-09-11T15:14:14+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-09-10T14:02:43+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-09-10T13:59:42+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2025-09-10T09:21:10+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-09-09T06:46:14+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Cancer","date":"2025-09-09T06:16:51+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-cancer","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bcan","sideBox":"Learn more about [BMC Cancer](http://bmccancer.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bcan/default.aspx","title":"BMC Cancer","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"8f490e09-9d6a-475e-97f0-b382f4bfc523","owner":[],"postedDate":"September 17th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2026-01-12T16:13:35+00:00","versionOfRecord":{"articleIdentity":"rs-7549251","link":"https://doi.org/10.1186/s12885-025-15506-w","journal":{"identity":"bmc-cancer","isVorOnly":false,"title":"BMC Cancer"},"publishedOn":"2026-01-05 15:58:45","publishedOnDateReadable":"January 5th, 2026"},"versionCreatedAt":"2025-09-17 19:41:31","video":"","vorDoi":"10.1186/s12885-025-15506-w","vorDoiUrl":"https://doi.org/10.1186/s12885-025-15506-w","workflowStages":[]},"version":"v1","identity":"rs-7549251","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7549251","identity":"rs-7549251","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}